ERCP术后高淀粉酶血症发生情况及其影响因素分析

Abstract
Figure/Table
References (25)
Related Citation (1)

Download: PDF (658 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the occurrence of hyperamylaseemia after endoscopic retrograde cholangiopancreatography (ERCP), and to analyze the factors affecting the occurrence of hyperamylaseemia, aiming to provide the prevention and treatment of hyperamylaseemia after ERCP in the future guide. Methods The clinical data of 112 patients who underwent ERCP treatment at the Hospital of Shunyi District Beijing from October 2015 to June 2019 were retrospectively analyzed, and they were divided into groups based on whether postoperative hyperamylaseemia occurred or not, logistic multiple regression model was used to analyze the influencing factors of hyperamylaseemia after ERCP. Results All 112 patients developed hyperamylaseemia after ERCP in 24 cases, and 88 cases did not develop hyperamylaseemia after ERCP. The incidence rate was 21.43%. The proportions of common bile duct stenosis and duodenal papillary diverticulum in the occurrence group were higher than those in the non-occurring group, and the levels of PT, GGT and TG were higher than those in the non-occurring group, and the differences were statistically significant (P ＜ 0.05). Univariate and multivariate logistic regression showed that common bile duct stenosis, duodenal papillary diverticulum, high PT level, high GGT level, and high TG level were the influencing factors of hyperamylaseemia after ERCP (OR ＞ 1, P ＜ 0.05). Conclusion Common bile duct stenosis, duodenal papillary diverticulum, high PT level, high GGT level, and high TG level may increase the risk of hyperamylaseemia after ERCP. The clinic should pay attention to the implementation of reasonable interventions for patients with the above risk factors. It may be of positive significance to reduce the incidence and improve the prognosis.

Key words： Endoscopic retrograde cholangiopancreatography Hyperamylaseemia Common bile duct stenosis Duodenal papillary diverticulum

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Zuoling GUO Ying YANG Na

Cite this article:

ZHOU Zuoling GUO Ying YANG Na. Analysis of the occurrence and influencing factors of hyperamylaseemia after ERCP[J]. 中国医药导报, 2021, 18(1): 103-106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I1/103

[1] Binmoeller KF，Nett A. ERCP：Time to take the lead off? [J]. Gastrointest Endosc，2017，86（6）：1066-1069.
[2] Liu SS，Chang XH，Song JT，et al. Risks of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis and Hyperamylasemia After Endoscopic Papillary Balloon Dilation：A Retrospective Analysis [J]. Surg Laparosc Endosc Percutan Tech，2019，29（4）：280-284.
[3] 周世文，刘斌，石向阳，等.吲哚美辛对ERCP术后高淀粉酶血症及胰腺炎的预防作用[J].肝胆外科杂志，2017， 25（2）：129-133.
[4] 王桂良，邱萍，徐林芳，等.4种蛋白酶抑制剂预防胆总管结石患者ERCP术后高淀粉酶血症和胰腺炎的成本-效果分析[J].中国药房，2017，28（14）：1880-1884.
[5] 范秀平，黄晓利，李晓辉，等.ERCP术后发生胰腺炎或高淀粉酶血症的相关因素分析[J].河北医学，2019，25（7）：1166-1169.
[6] Huang Q，Feng Shao F，Wang C，et al. Nasobiliary drainage can reduce the incidence of post-ERCP pancreatitis after papillary large balloon dilation plus endoscopic biliary sphincterotomy：a randomized controlled trial [J]. Scand J Gastroenterol，2018，53（1）：114-119.
[7] 徐莹，王蓓，余琼.治疗性经内镜逆行胰胆管造影术后高淀粉酶血症影响因素的研究[J].现代医学，2017，45（12）：1765-1768.
[8] Kato K，Shiba M，Kakiya Y，et al. Celecoxib Oral Administration for Prevention of Post-Endoscopic Retrograde Cho-langiopancreatography Pancreatitis：A Randomized Pro-spective Trial [J]. Pancreas，2017，46（7）：880-886.
[9] 依尔潘·艾山，高峰.经内镜逆行胰胆管造影术后高淀粉酶血症的危险因素分析[J].临床肝胆病杂志，2016，32（1）：119-122.
[10] 杨金伟，陈昊，苏锐良，等.内镜逆行胰胆管造影术后主要并发症的防治[J].中华肝胆外科杂志，2019，25（2）：149-154.
[11] 白晓庆，黄华，张映媛，等.经内镜逆行性胰胆管造影术后并发症的防治进展[J].胃肠病学和肝病学杂志，2017， 26（7）：837-840.
[12] 陈晓旭，林艺.526例ERCP术后胰腺炎及高淀粉酶血症原因分析[J].中国实验诊断学，2017，21（6）：1016-1018.
[13] 徐平平，曾春艳，龙顺华，等.经内镜逆行胰胆管造影术后并发症的危险因素分析[J].中华消化内镜杂志，2017， 34（10）：732-737.
[14] 马微微，王彬，李影.内镜下逆行胰胆管造影术后并发症的原因分析与护理对策[J].中国医刊，2017，52（1）：82-84.
[15] 潘宏伟，王晨，张艳.经内镜逆行胰胆管造影术后并发胰腺炎和高淀粉酶血症的危险因素分析[J].中国内镜杂志，2018，24（7）：26-32.
[16] Morling JR，Fallowfiele JA，Williamson RM，et al. γ-Glutamyltransferase，but not markers of hepatic fibrosis，is associated with cardiovascular disease in older people with type 2 diabetes mellitus：the Edinburgh Type 2 Diabetes Study [J]. Diabetologia，2015，58（7）：1484-1493.
[17] Wang J，Zhang D，Huang R，et al. Gamma-glutamyltransferase and risk of cardiovascular mortality：a dose-response meta-analysis of prospective cohort studies [J]. PLoS One，2017，12（2）：e0172631.
[18] 董永春.高脂血症性与胆源性急性胰腺炎患者血脂、血淀粉酶、尿淀粉酶水平的比较[J].胃肠病学和肝病学杂志，2017，26（7）：761-764.
[19] 浦清，龚玲，居培红，等.血清脂肪酶对60岁以上高脂血症性急性胰腺炎患者诊断的意义[J].江苏医药，2018， 44（1）：104-105.
[20] 蔡尚坤，蒋利，杨家印.术前血清谷氨酰胺转肽酶与肝癌患者活体肝移植术后生存的关系[J].中华普通外科杂志，2017，32（11）：945-948.
[21] 张亚飞，潘伟康，吴兵，等.ERCP引导下腔内射频消融联合支架置入治疗恶性胆管肿瘤合并梗阻的临床疗效及短期预后分析[J].解放军医药杂志，2017，29（9）：48-51.
[22] 陈雷，余保平，林梦娟.胆源性急性胰腺炎与高脂血症性急性胰腺炎的比较及急性胰腺炎与甘油三酯的相关性研究[J].胃肠病学和肝病学杂志，2017，26（7）：749-753.
[23] 刘瑶，李春亮，杨庆龙，等.代谢综合征患者经内镜逆行胰胆管造影术后并发症分析[J].中华消化内镜杂志，2017， 34（10）：728-731.
[24] 唐映，陈浩军，邝杰思，等.硫酸镁辅助治疗对急性胆源性胰腺炎十二指肠镜术后患者血清脂肪酶、淀粉酶、胆红素及肝功能影响研究[J].肝胆外科杂志，2017，25（5）：358-361.
[25] 钟爱丽，荣培姣，覃建宏.生长抑素联合头孢他啶预防内镜逆行胰胆管造影术后高淀粉酶血症和胰腺炎的临床观察[J].广西医学，2017，39（2）：269-271.